| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 59676-0340-01 | 59676-0340 | Erythropoietin | Procrit | 40000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 1, 1989 | In Use | ||
| 69468-0151-10 | 69468-0151 | Uridine Triacetate | Vistogard | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | Mar 1, 2016 | In Use | |
| 16729-0090-15 | 16729-0090 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jun 8, 2010 | In Use | |
| 16729-0090-16 | 16729-0090 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 15, 2011 | In Use | |
| 68071-1904-06 | 68071-1904 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 22, 2017 | In Use | |
| 58468-0180-01 | 58468-0180 | Sargramostim | Leukine | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Aug 5, 2013 | Jun 30, 2016 | No Longer Used | ||
| 00054-0143-07 | 00054-0143 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 24, 2008 | In Use | |
| 83980-0012-10 | 83980-0012 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 19, 2025 | In Use | |
| 55111-0153-13 | 55111-0153 | Ondansetron Hydrochloride | ONDANSETRON | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 26, 2006 | In Use | |
| 25021-0813-10 | 25021-0813 | Leucovorin Calcium | Leucovorin Calcium | 50.0 mg/5mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Sep 15, 2012 | In Use | |
| 70518-3600-03 | 70518-3600 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 1, 2023 | In Use | |
| 60505-1311-01 | 60505-1311 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 11, 2008 | Nov 1, 2010 | No Longer Used | |
| 00409-4215-05 | 00409-4215 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Mar 18, 2019 | Jun 1, 2022 | In Use | |
| 70860-0782-10 | 70860-0782 | Fosaprepitant dimeglumine | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Nov 30, 2020 | Jan 31, 2023 | No Longer Used |
| 68788-7565-03 | 68788-7565 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 27, 2019 | In Use | |
| 00944-2620-04 | 00944-2620 | Human Immunoglobulin G | GAMMAGARD | Ancillary Therapy | Immunostimulant | Human Immunoglobulin G | May 10, 1994 | Sep 2, 2015 | In Use | ||
| 33261-0417-20 | 33261-0417 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
| 30698-0120-05 | 30698-0120 | Dolasetron mesylate | Anzemet | 50.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 11, 1997 | May 24, 2021 | In Use |
| 70954-0652-10 | 70954-0652 | Finasteride and Tadalafil | Finasteride and Tadalafil | 5.0 mg/1, 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 24, 2025 | In Use | |
| 70121-2631-01 | 70121-2631 | FOSAPREPITANT DIMEGLUMINE | FOCINVEZ | 150.0 mg/50mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Jun 15, 2024 | In Use | |
| 68788-6976-06 | 68788-6976 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jun 6, 2017 | In Use | |
| 00781-2323-68 | 00781-2323 | Aprepitant | Aprepitant | 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 27, 2016 | In Use | |
| 43598-0303-90 | 43598-0303 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct 25, 2012 | In Use | |
| 43598-0671-11 | 43598-0671 | Fosaprepitant | Fosaprepitant | 150.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Mar 20, 2020 | In Use | |
| 55513-0097-91 | 55513-0097 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Sep 25, 2006 | Feb 28, 2009 | No Longer Used |
Found 12250 results — Export these results
Home